Sam Brusco, Associate Editor02.20.24
GT Medical Technologies (GT MedTech) announced that Per Langoe has joined the company as its new CEO.
Langoe was most recently co-founder, president, and CEO of Palette Life Sciences. During his tenure the company designed and navigated a complex, randomized controlled trial and subsequent regulatory approval process. After approval and commercialization—with emphasis on radiation oncologists—the company was acquired by Teleflex in 2023.
"I look forward to joining the GT MedTech team to help advance the mission of improving the lives of patients with brain tumors. Our goal is to collaborate with physicians to ensure patients have easy access to GammaTile. We strive to offer innovative options to optimize patient care," Langoe told the press.
The appointment comes as GT MedTech accelerates adoption of its GammaTile in the U.S. GammaTile is the only U.S. Food and Drug Administration (FDA)-cleared revolutionary innovation in brain brachytherapy, according to the company.
GammaTile is bioresorbable collagen embedded with Cesium-131 radioactive seeds that offer focused radiation to the brain tumor cavity, beginning at the time of tumor removal to help eradicate residual tumor cells and minimizing impact to healthy tissue.
Over 1,200 patients has undergone GammaTile therapy since it received FDA clearance in 2018 for recurrent brain tumors and 2020 for newly diagnosed malignant tumors.
Langoe succeeds Matt Likens, the founding CEO of GT MedTech who retired in January 2024.
"With more than 20 years managing commercial, clinical, M&A, and other functions at several successful MedTech companies, Per is uniquely suited to lead GT through its next phase of growth," said Kyle Dempsey, a member of GT's board of directors, "We are pleased to welcome Mr. Langoe to lead GT MedTech at this important inflection point and look forward to partnering with him to ensure even more doctors and patients have access to this innovative technology."
Langoe was most recently co-founder, president, and CEO of Palette Life Sciences. During his tenure the company designed and navigated a complex, randomized controlled trial and subsequent regulatory approval process. After approval and commercialization—with emphasis on radiation oncologists—the company was acquired by Teleflex in 2023.
"I look forward to joining the GT MedTech team to help advance the mission of improving the lives of patients with brain tumors. Our goal is to collaborate with physicians to ensure patients have easy access to GammaTile. We strive to offer innovative options to optimize patient care," Langoe told the press.
The appointment comes as GT MedTech accelerates adoption of its GammaTile in the U.S. GammaTile is the only U.S. Food and Drug Administration (FDA)-cleared revolutionary innovation in brain brachytherapy, according to the company.
GammaTile is bioresorbable collagen embedded with Cesium-131 radioactive seeds that offer focused radiation to the brain tumor cavity, beginning at the time of tumor removal to help eradicate residual tumor cells and minimizing impact to healthy tissue.
Over 1,200 patients has undergone GammaTile therapy since it received FDA clearance in 2018 for recurrent brain tumors and 2020 for newly diagnosed malignant tumors.
Langoe succeeds Matt Likens, the founding CEO of GT MedTech who retired in January 2024.
"With more than 20 years managing commercial, clinical, M&A, and other functions at several successful MedTech companies, Per is uniquely suited to lead GT through its next phase of growth," said Kyle Dempsey, a member of GT's board of directors, "We are pleased to welcome Mr. Langoe to lead GT MedTech at this important inflection point and look forward to partnering with him to ensure even more doctors and patients have access to this innovative technology."